Suggested remit: To appraise the clinical and cost effectiveness of teprotumumab within its marketing authorisation for treating thyroid eye disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6432

Provisional Schedule

Committee meeting 11 June 2025
Expected publication 20 August 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Amgen Limited (teprotumumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups British Thyroid Foundation
Professional groups Royal College of Ophthalmologists
  Royal College of Physicians
  Society for Endocrinology
Associated public health groups None
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
29 October 2024 Invitation to participate
18 July 2024 - 15 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6432
18 July 2024 In progress. Scoping commenced.
10 April 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual